Effects of Interleukin-12 in the Long-term Protection Conferred by a Mycobacterium avium Subunit Vaccine . FRONTLINES
- 1 December 2000
- journal article
- research article
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 52 (6) , 531-533
- https://doi.org/10.1046/j.1365-3083.2000.00816.x
Abstract
The effects of the addition of recombinant interleukin (IL)‐12 to a mycobacterial subunit vaccine were analyzed in terms of the longevity of the protective immunity generated. BALB/c mice were immunized with culture filtrate proteins from Mycobacterium avium with dimethyl‐dioctadecilammonium bromide (DDA) as an adjuvant. This subunit vaccine induced protection against a challenge by M. avium which lasted for at least 6 months while waning with time until 1 year postvaccination. Whereas the addition of IL‐12 enhanced the initial protective efficacy of this subunit vaccine during the first 6 months, it accelerated the loss of protective efficacy observed at 1 year postvaccination. These data confirm the adjuvant properties of IL‐12 in vaccines against mycobacteria and raise the possibility of late counter‐protective untoward effects.Keywords
This publication has 5 references indexed in Scilit:
- NEW VACCINES AGAINST TUBERCULOSIS: The Status of Current ResearchInfectious Disease Clinics of North America, 1999
- Protective Effect of Vaccination with a Combination of Recombinant Surface Antigen 1 and Interleukin-12 against Toxoplasmosis in MiceInfection and Immunity, 1998
- An IL-12-based vaccination method for preventing fibrosis induced by schistosome infectionNature, 1995
- The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania majorScience, 1994
- BCG vaccination against tuberculosis and leprosyBritish Medical Bulletin, 1988